Leen Kawas, a prominent figure in the biotechnology industry, is a passionate advocate for making the world’s energy more efficient. Speaking to an audience at the MIT Energy Conference, she said that energy efficiency could majorly affect some of the world’s most challenging problems, including climate change and economic growth.
What is Propel Bio Partners LP all about?
Propel Bio Partners LP is a global equity investment firm focused on investing in companies engaged in the development and commercialization of biotechnology. With a track record of working with many of the world’s most innovative life sciences companies, the Firm’s mission is to find, fund and guide those companies to success. The Firm provides access to its ecosystem of medical experts and seasoned entrepreneurs and its deep understanding of the life sciences industry. As an equity fund, it seeks to generate attractive returns for its investors by investing directly in companies in various sectors and stages with multiple investment strategies. While many biotechnology firms focus on R&D and product development, the Firm’s investing strategy focuses on companies generating revenues and actively contributing to society.
Leen Kawas has been a life-long advocate for innovation in the pharmaceutical and biotech industry. Instead of focusing solely on science, she has tried to promote biotechnology, urging investors to be creative and fight for a brighter future. Before joining Propel Bio Partners LP, Leen Kawas was the founder and CEO of many life sciences companies, including BioCryst Pharmaceuticals, Inc., Bechem Surgical Products Ltd and Cytovance Technologies Inc.
Original source to learn more: https://www.inherentbio.com/team/leen-kawas